• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines

tetano

Editor, Senior Moderator
Viruses. 2012 Nov 14;4(11):3090-108. doi: 10.3390/v4113090.
Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines.
Clementi N, Criscuolo E, Castelli M, Mancini N, Clementi M, Burioni R.
Source

Microbiology and Virology Unit, "Vita-Salute" San Raffaele University, Milan 20132, Italy. clementi.nicola@hsr.it.
Abstract

The emergence of new influenza strains causing pandemics represents a serious threat to human health. From 1918, four influenza pandemics occurred, caused by H1N1, H2N2 and H3N2 subtypes. Moreover, in 1997 a novel influenza avian strain belonging to the H5N1 subtype infected humans. Nowadays, even if its transmission is still circumscribed to avian species, the capability of the virus to infect humans directly from avian reservoirs can result in fatalities. Moreover, the risk that this or novel avian strains could adapt to inter-human transmission, the development of resistance to anti-viral drugs and the lack of an effective prevention are all incumbent problems for the world population. In this scenario, the identification of broadly neutralizing monoclonal antibodies (mAbs) directed against conserved regions shared among influenza isolates has raised hopes for the development of monoclonal antibody-based immunotherapy and "universal" anti-influenza vaccines.

PMID:
23202517
[PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/23202517
 
Back
Top Bottom